Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
June 28, 2017
6th Circ. Asked To Revive Spinal Patients' 'Disorganized' Suit
Spinal surgery patients who say they were given an unsafe biologic that caused excess bone growth and constant, incurable pain have asked the Sixth Circuit to revive their case, which was thrown out by a lower court in part because it was disorganized.
-
June 28, 2017
Cravath Leads Spectranetics In €1.9B Sale To Philips
Cravath Swaine & Moore LLP aided cardiovascular medical device company The Spectranetics Corp. in its €1.9 billion ($2.16 billion) sale to Netherlands-based health technology giant Royal Philips, an effort by the Dutch company to boost its image-guided therapy unit, that the pair announced Wednesday.
-
June 28, 2017
Deals Rumor Mill: Sebia, KKR, Halliburton
A French, private equity-backed medical diagnostic equipment manufacturer could sell for €2 billion or more, KKR will rake in £1.4 billion through the sale of its stake in a Norwegian software company, and Halliburton has its eye on a U.S. oilfield equipment supplier backed by billionaire George Kaiser.
-
June 28, 2017
Sorrento Investor Suit Survives Dismissal Bid
A Delaware judge refused Wednesday to dismiss a suit against directors of biopharma firm Sorrento Therapeutics Inc. over allegedly self-serving stock grants following an asset transfer, saying it's on the defendants to prove that the transactions were fair.
-
June 28, 2017
Leegin's 10-Year Checkup: No Big Changes In The Marketplace
The experience of the past decade simply has not borne out the U.S. Supreme Court dissent’s prediction that Leegin “will likely raise the price of goods at retail” and “create considerable legal turbulence as lower courts seek to develop workable principles,” says Michael Lockerby, co-leader of Foley & Lardner LLP's distribution and franchise practice group.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals